0001209191-17-009281.txt : 20170209 0001209191-17-009281.hdr.sgml : 20170209 20170209192732 ACCESSION NUMBER: 0001209191-17-009281 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170207 FILED AS OF DATE: 20170209 DATE AS OF CHANGE: 20170209 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS INC CENTRAL INDEX KEY: 0001175505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260038620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-365-5600 MAIL ADDRESS: STREET 1: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Knickerbocker Aron Marc CENTRAL INDEX KEY: 0001578766 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36070 FILM NUMBER: 17589104 MAIL ADDRESS: STREET 1: C/O FIVE PRIME THERAPEUTICS, INC. STREET 2: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-02-07 0 0001175505 FIVE PRIME THERAPEUTICS INC FPRX 0001578766 Knickerbocker Aron Marc TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080 1 1 0 0 Chief Operating Officer Common Stock 2017-02-07 4 A 0 9516 0.00 A 184557 D Common Stock 2017-02-07 4 A 0 5323 0.00 A 189881 D Employee Stock Option (right to buy) 45.38 2017-02-07 4 A 0 36920 0.00 A 2027-02-06 Common Stock 36920 36920 D Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 5, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date. The reporting person transferred 770 shares of common stock to his ex-wife pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-wife. Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on February 5, 2019 and two-thirds (2/3) of the restricted stock will vest on February 5, 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date. The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month beginning on March 7, 2017, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date. /s/ Francis Sarena, Attorney-in-fact 2017-02-09